The effect of cytostatic hexitol derivatives on haematopoietic stem cells, the L1210 leukaemia and C22LR osteosarcoma.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004988:Ethers, Cyclic / Q000494:pharmacology; D005260:Female; D004376:Galactitol / Q000031:analogs & derivatives / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D007275:Injections, Intravenous; D007928:Lethal Dose 50; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D008353:Mannitol / Q000031:analogs & derivatives / Q000494:pharmacology; D008698:Mesylates / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D008927:Mitobronitol / Q000494:pharmacology; D008936:Mitolactol / Q000494:pharmacology; D009150:Mustard Compounds / Q000494:pharmacology; D012516:Osteosarcoma / Q000188:drug therapy*; D011828:Radiation Chimera; D013402:Sugar Alcohols / Q000494:pharmacology
D000970:Antineoplastic Agents; D004988:Ethers, Cyclic; D008698:Mesylates; D009150:Mustard Compounds; D013402:Sugar Alcohols; D004376:Galactitol; D008353:Mannitol; D008927:Mitobronitol; D008936:Mitolactol